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Editorial Comment 
Are Beta-Blockers Really 
Underutilized in 
Postinfarction Patients?* 
ROBERT A. O 'ROURKE,  MD, FACC 
San Antonio, Texas 
Patients who survive an acute myocardial infarction are at 
increased risk for sudden death, nonsudden death and rein- 
farction. Accordingly, the aim of secondary prevention for such 
patients i to prolong life by preventing these vents during the 
follow-up period. In clinical trials performed before the advent 
of thrombolytic therapy and coronary angioplasty and before 
the frequent use of aspirin and angiotensin-converting enzyme 
inhibitors in postinfarction patients, treatment with beta- 
adrenergic blocking agents has been shown to improve long- 
term survival after myocardial infarction. 
Results of beta.blocker trials. At least 25 randomized trials 
including >23,000 patients have evaluated the long-term use of 
many beta-blockers after myocardial infarction (1). Overall, 
the mortality rate during follow-up among 12,140 patients 
assigned to beta-blocker therapy was 7.6% compared with 
9.4% among 11,551 control subjects (1). When performed, 
detailed analyses of the results based on various predefined 
subgroups has revealed no preferential treatment effect in any 
category. However, the absolute salutary effect of treatment 
has been far greater for the group of patients with a poor 
rather than a good prognosis (1). Of interest, a retrospective 
analysis with its limitations was performed in three clinical 
trials and showed little or no benefit with beta-blockers in
patients with non-Q wave infarctions (2). 
In the Beta-Blocker Heart Attack Trial (BHAT) (3), 3,837 
patients were randomized to either receive placebo or pro- 
pranolol in a dose of 180 or 240 rag/day. The total mortality 
rate during the average 25-month follow-up period was 7.2% in 
the propranolol group and 9.8% in the placebo group, a 
statistically significant difference. In a post hoc analysis (4), all 
enrolled patients in BHAT were classified on the basis of 
clinical findings in hospital before randomization (average 13.8 
days) into groups having electrical (rhythm) complications, 
mechanical (pump) complications, both electrical and mechan- 
ical complications and neither mechanical nor electrical com- 
plications. The long-term mortality rate in patients with no 
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complications (>50% of total) who received placebo was 
6.6%, no different from the 6.2% death rate in those who 
received propranolol. By contrast, here was a twofold increase 
in mortality in the placebo-group atients with electrical 
complications before randomization and a 60% increase in 
mortality in patients with mechanical complications who re- 
ceived placebo. In patients with both prerandomization elec- 
trical and mechanical complications, the mortality rate for 
propranolol was 12.9% compared with 17.1% for placebo. 
In the short-term Metoprolol in Acute Myocardial Infarc- 
tion (MIAMI) trial (5), 2,901 patients were randomized within 
24 h to placebo and 2,877 to metoprolol therapy (15 mg 
intravenously followed by 200 mg/day orally). During the study 
period of 15 days, 4.9% of patients died in the placebo group 
and 4.3% in the metoprolol group, a difference of 13% that 
was not statistically significant. In a retrospective analysis (5), 
patients were allocated to high or low risk groups on the basis 
of the presence or absence of more than two of eight variables. 
During follow up, metoprolol had no apparent effect in the low 
mortality risk group (3,740 patients) but was associated with a 
29% lower mortality rate (p < 0.033) in the high risk group 
(2,038 patients). 
By contrast, a benefit with timolol therapy (20 mg/day 
orally) was observed in the long-term Norwegian Timolol Trial 
(6) regardless of whether the patient had more than one 
myocardial infarction, a single myocardial infarction with high 
risk complications ora single myocardial infarction at low risk. 
In several other analyses (7-9) that were either etrospec- 
tive or utilized risk stratification data obtained after random- 
ization, long-term beta-blocker therapy appeared to be no 
different from placebo for women, patients <65 years old, 
nonsmokers and those categorized atlow or moderate risk. 
American College of Cardiology/American Heart Associa- 
tion clinical practice guidelines. The American College of 
Cardiology/American Heart Association (ACC/AHA) Task 
Force on Assessment of Diagnostic and Therapeutic Cardio- 
vascular Procedures published guidelines for the early man- 
agement of patients with acute myocardial infarction in August 
1990 (10). In these guidelines, which are currently being 
revised, indications for diagnostic procedures and therapeutic 
interventions were designated as class I when they are usually 
indicated, always acceptable and considered useful or effective. 
Class II designations were used when indications for proce- 
dures or interventions are acceptable, but of uncertain efficacy 
and sometimes controversial. Class II was subdivided into 
class IIA when the weight of evidence is in favor of usefulness/ 
efficacy and class liB when it is not well established by 
evidence, can be helpful and probably is not harmful. A class 
III designation denotes that the procedure or intervention is 
not indicated and may be harmful. 
In the ACC/AHA guidelines there is discussion of the 
usefulness of long-term beta-blocker therapy for secondary 
prevention in patients without myocardial revascularization. 
Listed contraindications for the use of beta-blockers in acute 
myocardial infarction include bradycardia, hypotension, mod- 
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erate to severe left ventricular failure, signs of peripheral 
hypoperfusion, atrioventricular conduction abnormalities and 
severe chronic obstructive pulmonary disease. Relative contra- 
indications listed are a history of asthma, current use of 
calcium channel blocking agents, severe peripheral vascular 
disease and difficult to control insulin-dependent diabetes. 
Class I designation was given for all but low risk postinfarc- 
tion patients who do not have a contraindication to beta- 
blockade. A class IIA classification was given to low risk 
patients with beta-blockade. Thus, these recommendations do 
not indicate that very low risk patients without contraindica- 
tions to beta-blockade should necessarily receive beta-blocker 
therapy. 
The ACC/AHA Task Force Report gave a class I designa- 
tion to postinfarction patients undergoing thrombolytic treat- 
ment for early intravenous beta-blocker therapy followed by 
oral administration for the patient with hypertension, reflex 
tachycardia, trial fibrillation with rapid ventricular response 
or postinfarction angina, provided that the usual contraindica- 
tions are absent. A class IIA designation was given to the early 
routine intravenous use of beta-blockers in all patients without 
contraindications. 
American Heart Association guide to comprehensive risk 
reductions in patients with coronary and other vascular 
diseases. In July 1995, the American Heart Association pub- 
lished a consensus panel statement on preventing heart attack 
and death in patients with coronary heart disease (11) that was 
endorsed by the Board of Trustees of the American College of 
Cardiology. The consensus panel statement includes a guide to 
comprehensive risk reduction for patients with coronary and 
other vascular disease. 
The recommendation in this guide is to start beta-blocker 
therapy in high risk postinfarction patients (arrhythmia, left 
ventricular dysfunction, inducible ischemia) without contrain- 
dications at 5 to 28 days and to continue for a 6-month 
minimum and to use beta-blockers as needed to manage 
angina and blood pressure in all other patients. 
Cardiologists' practices compared with practice guidelines. 
In this issue of the Journal, Brand et al. (12) measured 
cardiologist's level of adherence to the ACC/AHA guidelines 
for long-term use of beta-blockers after acute myocardial 
infarction by analyzing insurance claims for filled prescriptions 
from 17 network model health plans located throughout the 
United States. They assessed the practices of 150 cardiologists 
in relation to 280 patients (307 hospital admissions) who were 
plan members. Brand et al. used class I and class IIA criteria 
from the ACC/AHA report for compliance with the guidelines 
in using long-term beta-blockers for secondary prevention. 
They appropriately excluded patients with acute myocardial 
infarction undergoing revascularization. In their study, only 
48% of the patients (89 of 185) who were eligible were treated 
with beta-blocker therapy. Forty-three percent of cases (131 of 
307), involved apparent deviations from the guidelines; 11% 
(35 of 305) involved possible errors of commission (beta- 
blocker given despite acontraindication); and 31% (96 of 307) 
errors of omission (beta-blocker not given in the absence of a 
contraindication). Because Brand et al. include "diabetes 
mellitus" without further specification and "other specified 
cardiac dysrhythmias" ascontraindications, their assessment of 
patient eligibility for beta-blockade probably is lower than that 
used by most cardiologists. 
A major difficulty inherent in any study of this type is the 
absence of information concerning individual patient charac- 
teristics that might alter a decision to give or withhold a 
specific type of medical or surgical therapy. There is no 
information given concerning the patient's age, presence or 
absence of hypertension, site of the myocardial infarction and 
many other factors. As previously mentioned, the data con- 
cerning the benefit of long-term beta-blockers for patients with 
a non-Q wave myocardial infarction are inconclusive. Also, in 
1995 most patients at high risk on the basis of their clinical 
characteristics undergo cardiac catheterization, and many of 
these have subsequent angioplasty or coronary artery bypass 
graft surgery. This is an important consideration that is rele- 
vant because the patients at the highest risk in the absence of 
revascularization therapy benefit the most from long-term 
beta-blocker therapy. The cardiologist not prescribing long- 
term beta-blocker therapy for a patient with an uncomplicated 
acute inferior wall myocardial infarction who has no evidence 
of stress-induced myocardial ischemia, major arrhythmias or 
depressed left ventricular function is not necessarily out of 
compliance with current guidelines. Also, the dosages of the 
beta-blocker p escribed are not provided in the study by Brand 
et al. The number of eligible postinfarction patients receiving 
beta-blockers in the same doses as given in the clinical trials 
that showed their salutary effect has been reported to be as low 
as 11% (13). Often, the dose of beta-blocker prescribed long 
term is considerably lower than the dose used in studies uch as 
BHAT, MIAMI and the Norwegian Timolol Trial. 
Brand et al. provide interesting data concerning the per- 
centages of eligible patients who were placed on long-term 
beta-blocker therapy after myocardial infarction by different 
cardiologists from various sections of the United States using 
prescription data. Their findings are most likely more accurate 
than physician survey data and are consistent with previous 
reports. However, such studies lack specific patient informa- 
tion that might influence the decision for or against long-term 
beta-blocker therapy. The recently published guide to compre- 
hensive risk reduction for patients with coronary and other 
vascular disease by the AHA seems reasonable. Long-term 
beta-blockers definitely should be given to high risk postinfarc- 
tion patients without contraindications. This applies to high 
risk patients who do not undergo myocardial revascularization 
as part of their initial therapy and to many patients at high risk 
after successful myocardial revascularization. Beta-blockers 
also should be used as needed to manage angina, evidence of 
myocardial ischemia or high blood pressure in appropriate 
patients after myocardial infarction. Are beta-blockers eally 
underutilized by cardiologists in secondary prevention for 
postinfarction patients? The answer is yes, especially in high 
risk patients; the doses used are often lower than those proved 
to be efficacious, and these drugs are underutilized in elderly 
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patients (14). However, each individual patient should be 
considered separately, and guidelines are not a mandate for 
compliance with a certain therapeutic regimen. 
References  
1. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical 
trials in heart disease. JAMA 1988;260:2088-93. 
2. Gibson RS. Non-Q-wave myocardial infarction: diagnosis, prognosis, and 
management. Curr Probl Cardiol 1988;13:5-72. 
3. Beta-blocker Heart Attack Trial Research Group. A randomized trial of 
propranolol in patients with acute myocardial infarction. JAMA 1982;247: 
1707-14. 
4. Furberg CD, Hawkins CM, Lichstein E, for the Beta-Blocker Heart Attack 
Trial Study Group. Effect of propranotol in postinfarction patients with 
mechanical or electrical complications. Circulation 1984;69:761-5. 
5. The Miami Trial Research Group. Metoprolol in acute myocardial infarction 
(MIAMI): a randomised placebo-controlled international trial. Eur Heart J
1985;6:199-226. 
6. The Norwegian Multicenter Study Group. Timolol-induced reduction in 
mortality and reinfarction i  patients urviving acute myocardial infarction. 
New Engl J Med 1981;304:801-7. 
7. Petersen TR, for The Norwegian Multicenter Study Group. Six-year 
follow-up of the Norwegian multicenter study on timolol after acute 
myocardial infarction. N Engl J Med 1985;313:1055-8. 
8. Jafri SM, Tilley BC, Peters R, Schultz LR, Goldstein S. Effects of cigarette 
smoking and propranolol in survivors of acute myocardial infarction. Am J 
Cardiol 1990;65:271-6. 
9. Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial infarc- 
tion: influence of first-year clinical course on long-term effectiveness. Ann 
Intern Med 1993;118:99-105. 
10. Gunnar RM, Bourdillon PDV, Dixon DW, et al. ACC/AHA Task Force 
Report. Guidelines for the early management of patients with acute myo- 
cardial infarction. J Am Coil Cardiol 1990;16:249-92, Circulation 1990;82: 
664 -707. 
11. Smith SC, Blair SN, Criqui MH, et al. AlIA Medical/Scientific Statement, 
Consensus Panel Statement. Preventing heart attack and death in patients 
with coronary disease. Circulation 1995;92:2-4. 
12. Brand DA, Newcomer LN, Freiburger A, Tian Hao. Cardiologists' practices 
compared with practice guidelines: use of beta-blockade after acute myocar- 
dial infarction. J Am Coll Cardiol 1995;26:1432-6. 
13. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking 
agents after myocardial infarction: from randomized trials to clinical prac- 
tice. J Am Coil Cardiol 1995;25:1327-32. 
14. Gurwitz JH, Goldberg RJ, Chert Z, Gore JM, Alpert JS./3-Blocker therapy 
in acute myocardial infarction: evidence for underutilization in the elderly. 
Am J Med 1992;93:605-10. 
